Tag Archives: Senate

Maryland General Assembly Overrides Veto to Enact Bill Increasing Minimum Wage to $15

On March 22, 2019, we wrote that the two houses of the Maryland General Assembly had agreed on a conference report adopting the Senate’s version of a bill that would increase the state-wide minimum wage to $15 by 2025 or 2026, depending on the size of the company, with two minor changes. We also discussed the bill on March 18, 2019.

Read more

Read full article

Senate Confirms John Ring to Restore Full Five-Member Board

On Wednesday, the Senate narrowly confirmed John Ring, a management-side labor attorney from Morgan Lewis & Bockius LLP, to the National Labor Relations Board (“NLRB” or the “Board”).  With this vote, Ring fills the last remaining open seat on the Board, which was previously held by former Chairman Philip Miscimarra.  Ring’s term will expire on December 16, 2022.  The confirmation vote of 50-48 was largely down party lines, with only two Democrats voting in favor of Ring’s confirmation.  The strong opposition from the Democrats is likely due to the perceived efforts of the Trump administration to install pro-business members to the Board.  Several prominent Democratic senators, including Patty Murray (D-Wash.) and Elizabeth Warren (D-Mass.), made very critical statements about Ring ahead of the vote.

Read more

Read full article
ILN Today Post

New Jersey: Senator proposes tax credit for EpiPen retailers

Much has been made in recent weeks of what the media has characterized as manufacturer Mylan’s steep,soaring, and massive price increase of the EpiPen, an epinephrine injection system that provides emergency treatment for life threatening allergic reactions. More specifically, the Guardian reported that when Mylan acquired the rights to EpiPen in 2007, the price was $56.64. Since then, that price has increased 461 percent, to $317.82. Quoting a letter that several Democratic senators, including Bernie Sanders, Elizabeth Warren and Sherrod Brown, sent to Mylan’s chief executive officer, Heather Bresch, the paper highlighted the issue:

[M]aking sure the EpiPen is readily available for use is a critical part of life for millions of Americans living with severe allergies…The EpiPen, however, has become so exorbitantly expensive that access to this life-saving combination product is in jeopardy for many Americans. Mylan’s near monopoly on the epinephrine auto-injector market has allowed [Mylan] to increase prices well beyond those that are justified by any increase in the costs of manufacturing the EpiPen.

Read More

Read full article

New FDA Draft Guidance Shows Limited Compromise with Brand and Generic Drug Manufacturers

The Food and Drug Administration (FDA) issued a draft guidance (Draft Guidance) on July 11, 2016 that allows some generic drug manufacturers holding an Abbreviated New Drug Application (ANDA) to update the label of the drug they manufacture with new safety information.  The Draft Guidance provides new clarifications and recommendations to generic drug manufacturers seeking to update a generic label after withdrawal by the name brand manufacturer of the reference listed drug (RLD) (a “Withdrawn RLD”).  The Draft Guidance explains how a generic manufacturer may submit an updated label of a generic drug to the FDA for approval after withdrawal of the RLD.  The FDA must approve the proposed new label before the new generic label may be issued.  The Draft Guidance also reminds applicants that the FDA continues to retain the authority to request the ANDA-holder with a Withdrawn RLD to update the label of the drug under its ANDA for safety reasons.

Read full article